Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Oral Doses of BI 1356 BS Administered to Healthy Male Subjects

Phase 1

Completed

• Conditions: Healthy
• Interventions: Drug: Placebo; Drug: BI 1356 BS - Tablet; Drug: BI 1356 BS - Powder in bottle (PIB)

• Registration Number: NCT02173665
• Lead Sponsor: Boehringer Ingelheim

Brief Summary

The objective of the current study was to investigate safety, tolerability, pharmacokinetics and pharmacodynamics of BI 1356 BS.

Detailed Description

Not available

Study Timeline

• Study Start: 2004-10
• Primary Completion: 2004-12
• Study First Submitted: 2014-06-24
• Study First Submitted QC: 2014-06-24
• Study First Posted: 2014-06-25
• Status Verified: 2014-07
• Last Update Submitted: 2014-07-04
• Last Update Posted: 2014-07-08

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Male
• Target Recruitment: 64

Inclusion Criteria

• Healthy males according to the following criteria: Based upon a complete medical history, including the physical examination, vital signs (Blood pressure (BP), Heart Rate (HR), 12-lead Electrocardiogram (ECG)), clinical laboratory tests

• Age ≥21 and Age ≤65 years
• BMI ≥18.5 and BMI ≤ 29.9 kg/m2 (Body Mass Index)
• Signed and dated written informed consent prior to admission to the study in accordance with Good Clinical Practice (GCP) and the local legislation

Exclusion Criteria

• Any finding of the medical examination (including BP, HR and ECG) deviating from normal and of clinical relevance
• Any evidence of a clinically relevant concomitant disease
• Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders
• Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurological disorders
• History of relevant orthostatic hypotension, fainting spells or blackouts
• Chronic or relevant acute infections
• History of relevant allergy/hypersensitivity (including allergy to the drug or its excipients and lactose intolerance)
• Intake of drugs with a long half-life (> 24 hours) within at least one month or less than 10 half-lives of the respective drug prior to administration or during the trial
• Use of drugs which might reasonably influence the results of the trial based on the knowledge at the time of protocol preparation within 10 days prior to administration or during the trial
• Participation in another trial with an investigational drug within two months prior to administration or during the trial
• Smoker (> 10 cigarettes or > 3 cigars or > 3 pipes/day)
• Inability to refrain from smoking on trial days
• Alcohol abuse (more than 60 g/day)
• Drug abuse
• Blood donation (more than 100 mL within four weeks prior to administration or during the trial)
• Excessive physical activities (within one week prior to administration or during the trial)
• Any laboratory value outside the reference range that is of clinical relevance
• Inability to comply with dietary regimen of study centre
• Any ECG value outside of the reference range and of clinical relevance including, but not limited to QRS interval > 110 ms or QTcB > 450 ms or QT >500 ms

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Placebo	Placebo	-
BI 1356 BS - Tablet	BI 1356 BS - Tablet	-
BI 1356 BS - Powder in bottle (PIB)	BI 1356 BS - Powder in bottle (PIB)	-

Primary Outcome Measures

Name	Time	Method
Number of patients with clinically significant changes in vital signs (blood pressure [BP], heart rate [HR])	Screening, up to 16 days after drug administration
Number of patients with abnormal changes in laboratory parameters	Screening, up to 16 days after drug administration
Assessment of tolerability by investigator on a 4-point scale	up to 16 days after drug administration
Number of patients with adverse events	up to 30 days
Number of patients with abnormal findings in physical examination	Screening, up to 16 days after drug administration
Number of patients with clinically significant changes in 12-lead electrocardiogram (ECG)	Screening, up to 16 days after drug administration

Secondary Outcome Measures

Name	Time	Method
AUC0-tz (area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the time of the last quantifiable data point)	predose, up to 192 h following drug administration
t1/2 (terminal half-life of the analyte in plasma)	predose, up to 192 h following drug administration
tmax (time from dosing to maximum concentration)	predose, up to 192 h following drug administration
%AUCtz-∞ (the percentage of the AUC0-∞ that is obtained by extrapolation)	predose, up to 192 h following drug administration
Vz/F (apparent volume of distribution during the terminal phase λz following an extravascular dose)	predose, up to 192 h following drug administration
Cmax (maximum concentration of the analyte in plasma)	predose, up to 192 h following drug administration
AUC0-∞ (area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity)	predose, up to 192 h following drug administration
MRTpo (mean residence time of the analyte in the body after po administration)	predose, up to 192 h following drug administration
CLR,t1-t2 (renal clearance of the analyte from the time point t1 until the time point t2)	up to 120 h following drug administration
λz (terminal rate constant in plasma)	predose, up to 192 h following drug administration
CL/F (total clearance of the analyte in the plasma after extravascular administration)	predose, up to 192 h following drug administration
fet1-t2 (fraction of analyte eliminated in urine from time point t1 to time point t2)	up to 120 h following drug administration
Aet1-t2 (amount of analyte that is eliminated in urine from the time point t1 to time point t2)	up to 120 h following drug administration
Changes of Dipeptidyl-Peptidase IV (DPP-IV) activity in plasma	predose, up to 96 h following drug administration